Incyte Corp. (NASDAQ:INCY)‘s stock had its “buy” rating restated by Jefferies Group in a research report issued to clients and investors on Tuesday.

Other equities research analysts have also recently issued research reports about the company. Leerink Swann reiterated an “outperform” rating and set a $98.00 price objective on shares of Incyte Corp. in a research note on Wednesday, October 12th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $101.00 price objective on shares of Incyte Corp. in a research note on Thursday, November 3rd. Barclays PLC increased their price target on Incyte Corp. from $85.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, August 10th. RBC Capital Markets set a $113.00 price target on Incyte Corp. and gave the company a “buy” rating in a research note on Wednesday, October 12th. Finally, Piper Jaffray Cos. set a $99.00 price target on Incyte Corp. and gave the company a “buy” rating in a research note on Wednesday, September 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty-one have assigned a buy rating to the company. Incyte Corp. has a consensus rating of “Buy” and a consensus price target of $104.98.

Analyst Recommendations for Incyte Corp. (NASDAQ:INCY)

Shares of Incyte Corp. (NASDAQ:INCY) opened at 104.13 on Tuesday. Incyte Corp. has a 52 week low of $55.00 and a 52 week high of $118.49. The firm has a market cap of $19.62 billion, a P/E ratio of 139.96 and a beta of 0.79. The stock has a 50 day moving average of $90.42 and a 200 day moving average of $83.27.

In other news, EVP Paula J. Swain sold 10,000 shares of the firm’s stock in a transaction dated Thursday, October 20th. The stock was sold at an average price of $90.00, for a total transaction of $900,000.00. Following the completion of the transaction, the executive vice president now directly owns 39,248 shares in the company, valued at $3,532,320. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Barry P. Flannelly sold 24,204 shares of the firm’s stock in a transaction dated Friday, October 7th. The stock was sold at an average price of $97.00, for a total value of $2,347,788.00. Following the transaction, the executive vice president now owns 13,595 shares of the company’s stock, valued at $1,318,715. The disclosure for this sale can be found here. Insiders own 13.70% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. NF Trinity Capital Hong Kong Ltd acquired a new stake in shares of Incyte Corp. during the third quarter worth $7,072,000. Northern Trust Corp increased its stake in shares of Incyte Corp. by 4.5% in the third quarter. Northern Trust Corp now owns 926,249 shares of the biopharmaceutical company’s stock worth $87,336,000 after buying an additional 39,757 shares during the last quarter. Columbus Circle Investors increased its stake in shares of Incyte Corp. by 17.3% in the third quarter. Columbus Circle Investors now owns 210,283 shares of the biopharmaceutical company’s stock worth $19,828,000 after buying an additional 30,951 shares during the last quarter. Westpac Banking Corp increased its stake in shares of Incyte Corp. by 11.5% in the third quarter. Westpac Banking Corp now owns 10,798 shares of the biopharmaceutical company’s stock worth $1,018,000 after buying an additional 1,117 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Incyte Corp. by 2.9% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 344,410 shares of the biopharmaceutical company’s stock worth $32,474,000 after buying an additional 9,635 shares during the last quarter. Institutional investors own 92.40% of the company’s stock.

About Incyte Corp.

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corp. and related stocks with our FREE daily email newsletter.